ACTA MEDICINAE 1/2014 Biologická léčba

Kompletní literatura

2 Nové monoklonální protilátky v nenádorových indikacích
prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie 1. LF UK a VFN, Praha
MUDr. Zdenka Hrušková, Ph.D. Klinika nefrologie a Ústav imunologie a mikrobiologie VFN a 1. LF UK, Praha

2 Biologická léčba systémového lupus erythematodes
MUDr. Zdenka Hrušková, Ph.D. Klinika nefrologie a Ústav imunologie a mikrobiologie VFN a 1. LF UK, Praha
prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie VFN a 1. LF UK, Praha

2 Nové možnosti léčby maligního melanomu
prof. MUDr. Karel Pizinger, CSc. Lékařská fakulta UK a FN, Plzeň

3 Biologická léčba ANCA-asociované vaskulitidy
MUDr. Zdenka Hrušková, Ph.D. Klinika nefrologie a Ústav imunologie a mikrobiologie VFN a 1. LF UK, Praha
prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie VFN a 1. LF UK, Praha

3 Novinky a současné možnosti biologické léčby metastatického kolorektálního karcinomu
MUDr. Igor Kiss, Ph.D. Klinika komplexní onkologické péče, MOÚ, Brno

3 Vismodegib v léčbě pokročilého bazocelulárního karcinomu
MUDr. Alena Fialová Dermatovenerologická klinika FN KV, Praha

4 Biologická léčba karcinomu prsu a novinky v roce 2013
MUDr. Marta Krásenská Klinika komplexní onkologické péče, MOÚ, Brno

4 Nové možnosti v medikamentózní léčbě idiopatických střevních zánětů
prof. MUDr. Milan Lukáš, CSc. Klinické a výzkumné centrum pro střevní záněty, ISCARE Lighthouse a 1. LF UK, Praha

4 Systémová terapie pokročilého světlobuněčného karcinomu ledviny v roce 2013
MUDr. Kateřina Kubáčková Onkologická klinika, 2. LF UK a FN Motol, Praha

5 Biologická léčba roztroušené sklerózy
doc. MUDr. Radomír Taláb, CSc. Neurologie, Hradec Králové
MUDr. Marika Talábová Neurologická klinika LF UK a FN, Hradec Králové

5 Biologická léčba v oftalmologii
doc. MUDr. Svatopluk Synek, CSc. Klinika nemocí očních a optometrie LF MU a FN u sv. Anny, Brno

6 Možnosti a postavení biologických léčiv v terapii chronických virových hepatitid B a C
doc. MUDr. Petr Urbánek, CSc. Interní klinika 1. LF UK a Ústřední vojenská nemocnice – Vojenská fakultní nemocnice, Praha

6 Preventivní očkování před zahájením cílené léčby u pacientů se solidními nádory
doc. MUDr. Tomáš Büchler Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

7 Biologická léčba idiopatické plicní fibrózy
doc. MUDr. Martina Vašáková, Ph.D. Pneumologická klinika 1. LF UK, Thomayerova nemocnice Praha

Nové monoklonální protilátky v nenádorových indikacích

prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie 1. LF UK a VFN, Praha
MUDr. Zdenka Hrušková, Ph.D.
Klinika nefrologie a Ústav imunologie a mikrobiologie VFN a 1. LF UK, Praha

1 **Baeten, D. – Baraliakos, X. – Braun, J., et al.**: Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet*, 2013, 382, s. 1705–1713.
2 **Erickson, H. K. – Lambert, J. M.**: ADME of antitody – maytansinoid conjugates. *AAPS Journal*, 2012, 14, s. 799–805.
3 **Farnier, M.**: PCSK9: from discovery to therapeutic applications. *Arch Cardiovasc Dis*, 2013, doi: 10.1016/j.acvd.2013.10.007.
4 **Genovese, M. C. – Durez, P. – Richards, H. B.**: Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. *Ann Rheum Dis*, 2013, 72, s. 863–869.
5 **Hueber, W. – Sands, B. E. – Lewitzky, S., et al.**: Secukinumamb, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut*, 2012, 61, s. 1693–1700.
6 **Kappos, L. – Li, D. – Calabresi, P. A., et al.**: Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. *Lancet*, 2011, 378, s. 1779–1787.
7 **Koren, M. J. – Giugliano, R. P. – Raal, F. J., et al.**: Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-weeks results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. *Circulation*, 2013, ePub před tiskem.
8 **Leonardi, C. – Matheson, R. – Zachariae, C., et al.**: Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. *N Engl J Med*, 2012, 366, s. 1190–1199.
9 **May, C. – Sapra, P. – Gerber, H.-P., et al.**: Advances in bispecific biotherapeutics for the treatment of cancer. *Biochemical Pharmacology*, 2012, 84, s. 1105–1112.
10 **McClung, M. R. – Grauer, A. – Boonen, S., et al.**: Romosozumab in postmenopausal women with low bone mineral density. *N Engl J Med*, 2014, doi: 10.1056/NEJMoa1305224.
11 **Mysler, E. F. – Spindler, A. J. – Guzman, R., et al.**: Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. *Arthritis Rheum*, 2013, 65, s. 2368–2379.
12 **Nelson, A. L. – Dhimolea, E. – Reichert, J. M.**: Development trends for human monoclonal antibody therapeutics. *Nat Rev Drug Discovery*, 2010, 9, s. 767–774.
13 **Papp, K. A. – Langley, R. G.. – Sigurgeirsson, B., et al.**: Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. *Br J Dermatol*, 2013, 168, s. 412–421.
14 **Pavord, I. D. – Korn, S. – Howarth, P., et al.**: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*, 2012, 380, s. 651–659.
15 **Reichert, J. M.**: Which are the antibodies to watch in 2013? *mAbs*, 2013, 5, s. 1–4.
16 **Reichert, J. M.**: Antibodies to watch in 2013. Mid-year update. *mAbs*, 2013, 5, s. 513–517.
17 **Reichert, J. M.**: Antibodies to watch in 2014. *mAbs*, 2013, 6, s. 1–10.
18 **Rich, P. – Siguirgeirsson, B. – Thaci, D., et al.**: Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. *Br J Dermatol*, 2013, 168, s. 402–411.
19 **Shimamoto, G. – Gegg, C. – Quéva, C.**: Peptibodies. A flexible alternative format to antibodies. *mAbs*, 2012, 4, s. 586–591.
20 **Goede, V. – Fischer, K. – Busch, R., et al.**: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*, 8. 1. 2014, publikováno před tiskem.

Biologická léčba systémového lupus erythematodes

MUDr. Zdenka Hrušková, Ph.D.
Klinika nefrologie a Ústav imunologie a mikrobiologie VFN a 1. LF UK, Praha
prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie VFN a 1. LF UK, Praha

1 **Závada, J.**: Léčba systémového lupus erythematodes. *Postgr Med. Revmatologie*, 2009, 9, dostupné online z: http://zdravi.e15.cz/clanek/postgradualni-medicina/lecba-systemoveho-lupus-erythematodes-447988, vyhledáno 18. 11. 2013.
2 **Tesar, V. – Hruskova, Z.**: Treatment of proliferative lupus nephritis: a slowly changing landscape. *Nat Rev Nephrol*, 2011, 7, s. 96–109.
3 **Wallace, D. J. – Stohl, W. – Furie, R. A., et al.**: A phase II, randomized, doubleblind, placebocontrolled, doseranging study of belimumab in patients with active systemic lupus erythematosus. *Arthritis Rheum*, 2009, 61, s. 1168–1178.
4 **Navarra, S. V. – Guzmán, R. M. – Gallacher, A. E., et al.**: BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*, 2011, 377, s. 721–731.
5 **Furie, R. – Petri, M. – Zamani, O., et al.**: BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum*, 2011, 63, s. 3918–3930.
6 **Wallace, D. J. – Navarra, S. – Petri, M. A., et al.**: BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. *Lupus*, 2013, 22, s. 144–154.
7 **Dooley, M. A. – Houssiau, F. – Aranow, C., et al.**: BLISS-52 and -76 Study Groups. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. *Lupus*, 2013, 22, s. 63–72.
8 **Duxbury, B. – Combescure, C. – Chizzolini, C.**: Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. *Lupus*, 2013, 22, s. 1489–1503.
9 **Weidenbusch, M. – Römmele, C. – Schröttle, A. – Anders, H. J.**: Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. *Nephrol Dial Transplant*, 2013, 28, s. 106–111.
10 **Merrill, J. T. – Neuwelt, C. M. – Wallace, D. J., et al.**: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum*, 2010, 62, s. 222–233.
11 **Rovin, B. H. – Furie, R. – Latinis, K., et al.**: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum*, 2012, 64, s. 1215–1226.

Nové možnosti léčby maligního melanomu

prof. MUDr. Karel Pizinger, CSc. Lékařská fakulta UK a FN, Plzeň

1 **Carvajal, R. D., et al.**: KIT as a target in metastatic melanoma. *JAMA*, 2011, 305, s. 2327–2334.
2 **Chapman, P. B. – Hauschild, A. – Robert, C. – Haanen, J. B., et al.**: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011, 364, s. 2507–2516.
3 **Guo, J., et al.**: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. *J Clin Oncol*, 2011, 29, s. 2904–2909.
4 **Heneberg, P.**: Pokroky v klinické léčbě zhoubného melanomu: inhibice kinázy B-RAF. *Klin Onkol*, 2011, 24, s. 256–264.
5 National Cancer Institute: http://www.cancer.gov/cancertopics/types/melanoma, vyhledáno 9. 12. 2013.
6 **Pflugfelder, A., et al.**: Malignant Melanoma S3-Guideline "Diagnosis, Therapy and Follow-up of Melanoma". *JDDG*, 2013, 11 (dopl. 6), s. 1–116.
7 **Wolchok, J. D., et al.**: Nivolumab plus ipilimumab in advanced melanoma. *N Eng J Med*, 2013, 369, s. 122–133.

Biologická léčba ANCA-asociované vaskulitidy

MUDr. Zdenka Hrušková, Ph.D.
Klinika nefrologie a Ústav imunologie a mikrobiologie VFN a 1. LF UK, Praha
prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie VFN a 1. LF UK, Praha

1 **Jennette, J. C – Falk, R. J. – Bacon, P. A., et al.**: 2012 Revised international Chapel Hill Consensus Conference nomenclature of vasculitides. *Arthritis & Rheum*, 2013, 65, s. 1–11.
2 **Mukhtyar, C. – Guillevin, L. – Cid, M. C., et al.**: EULAR Recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis*, 2009, 68, s. 310–317.
3 **Keogh, K. A. – Ytterberg, S. R. – Fervenza, F. C. – Carlson, K. A. – Schroeder, D. R. – Specme, U.**: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. *Am J Respir Crit Care Med*, 2006, 173, s. 180–187.
4 **Stasi, R. – Stipa, E. – Del Poeta, G. – Amadori, S. – Newland, A. C. – Provan, D.**: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. *Rheumatology*, 2006, 45, s. 1432–1436.
5 **Aries, P. M. – Hellmich, B. – Voswinkel, J., et al.**: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. *Ann Rheum Dis*, 2006, 65, s. 853–858.
6 **Alberici, F. – Jayne, D. R.**: Impact of rituximab trials on the teratment of ANCA-associated vasculitis. *Nephrol Dial Transplant*, 2013, 14. října – Epub před tiskem.
7 **Jones, R. B. – Ferrari, A. J. – Chaudhry, A. N.**: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*, 2009, 60, s. 2156–2168.
8 **Jones, R. B. – Tervaert, J. W. – Hauser, T., et al.**: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med*, 2010, 363, s. 211–220.
9 **Stone, J. H. – Merkem, P. A. – Spirea, R., et al.**: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*, 2010, 363, s. 221–232.
10 **Cartin-Ceba, R. – Golbin, J. M. – Keogh, K. A., et al.**: Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten year experience at a single center. *Arthritis Rheum*, 2012, 64, s. 3770–3778.
11 **Smith, R. M. – Jones, R. B. – Guerry, M. J., et al.**: Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*, 2012, 64, s. 3760–3769.
12 **Guillevin, L. – Pagnoux, C., et al.**: FVSG. MAINtenance of remission using RITuximab for Systemic ANCA-associated vasculitides (abstrakt A 66). ANCA Workshop 2013, Paříž, Francie.
13 **Jayne, D.**: What place for the new biologics in the treatment of necrotising vasculitides. *Clin Exp Rheumatol*, 2006, 24 (dopl. 41), s. 1–5.
14 **Booth, A. – Harper, L. – Hammad, T., et al.**: Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. *J Am Soc Nephrol*, 2004, 15, s. 717–721.
15 **Stone, J. H. – Uhlfelder, M. L. – Hellmann, D. B. – Crook, S. – Bedocs, N. M. – Hoffman, G. S.**: Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. *Arthritis Rheum*, 2001, 44, s. 1149–1154.
16 **Wegener's Granulomatosis Etanercept Trial (WGET) Research Group**: Etanercept plus standard therapy for Wegener's granulomatosis. *N Engl J Med*, 2005, 352, s. 351–361.
17 **Stone, J. H. – Holbrook, J. T. – Marriott, M. A., et al; Wegener's Granulomatosis Etanercept Trial Research Group**: Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. *Arthritis Rheum*, 2006, 54, s. 1608–1618.
18 **Walsh, M. – Chaudhry, A. – Jayne, D. R.**: Long-term follow-up of relapsing/refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). *Ann Rheum Dis*, 2008, 67, s. 1322–1327.

Novinky a současné možnosti biologické léčby metastatického kolorektálního karcinomu

MUDr. Igor Kiss, Ph.D. Klinika komplexní onkologické péče, MOÚ, Brno

1 **Primrose, J. N. – Falk, S. – Jones, M. J., et al.**: A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. *s. l. J Clin Oncol*, 2013, 31 (dopl.; abstrakt 3504).
2 **Nordlinger, B. – Sorbye, H. – Glimelius, B.**: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet*, 2008, 371, s. 1007–1016.
3 **Nordlinger, B. – Sorbye, H. – Glimelius, B., et al.**: Perioperative FOLFO4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncology*, 2013, s. 1208–1215.
4 **Heinemann, V. – Fischer, L. F. – Decker, T., et al.**: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). *J Clin Oncol*, 2013, 31 (dopl.; abstrakt LBA3506).
5 **Stintzing, S. – Jung, A. – Rossius, L., et al.**: Analýza mutací KRAS/NRAS a BRAF ve studii FIRE-3: Randomizovaná studie fáze III hodnotící kombinovanou biochemoterapii FOLFIRI plus cetuximab oproti FOLFIRI plus bevacizumab u pacientů s metastazujícím kolorektálním karcinomem (mCRC) s divokým typem (WT). *ESMO*, 2013, abstrakt LBA17.
6 **Schwartzberg, L. S., et al.**: Phase II PEAK Trial: First-line mFOLFOX6 + Panitumumab or Bevacizumab in mCRC. *ASCO GI*, 2013, abstrakt 446.
7 **Oliner, K. S. – Douillard, J. Y. – Siena, S., et al.**: Annalysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as fisrt-line treatment for metastatic colorectal cancer (mCRC). *ASCO*, 2013, abstrakt 3511.
8 **Falcone, A. – Cremolini, Ch. – Masi, G., et al.**: FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. *J Clin Oncol*, 2013, 31 (dopl.; abstrakt 3505).
9 **Saunders, M. P. – Lang, I. – Marcuello, E., et al.**: Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer. *J Clin Oncol*, 2013, 31 (dopl.; abstrakt 3521).
10 **Koopman, M. – Simkens, L. H. J. – Albert, J., et al.**: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). *J Clin Oncol*, 2013, 31 (dopl.; abstrakt 3502).
11 **Koeberle, D. – Betticher, D. C. – Moos, R., et al.**: Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06). *J Clin Oncol*, 2013, 31 (dopl.; abstrakt 3503).
12 **Van Cutsem, E. – Tabernero, J. – Lakomy, R., et al.**: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol*, 2012, 30, s. 3499–3506.
13 **Grothey, A. – Van Cutsem, E. – Sobrero, A., et al.**: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*, 2013, 381, s. 303–312.
14 **Cunningham, D. – Wong, R. P. – D'haens, G., et al.**: A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results. *J Clin Oncol*, 2008, abstrakt 4025.
15 **Hoff, P. M. – Hochhaus, A. – Pestalozzi, B. C., et al.**: Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). *J Clin Oncol*, 2012, 30, s. 3596–3603.
16 **Schmoll, H. J. – Cunningham, D. – Sobrero, A., et al.**: Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). *J Clin Oncol*, 2012, 30, s. 3588–3595.

Vismodegib v léčbě pokročilého bazocelulárního karcinomu

MUDr. Alena Fialová Dermatovenerologická klinika FN KV, Praha

1 SPC přípravku Erivedge (vismodegib).
2 **Epstein, E. H.**: Basal cell carcinomas: attack of the hedgehog. *Nat Rev Cancer*, 2008, 8, s. 743–754.
3 **Sekulic, A., et al.**: *J Clin Oncol*, 2013, 31 (dopl.), abstrakt 9037.

Biologická léčba karcinomu prsu a novinky v roce 2013

MUDr. Marta Krásenská Klinika komplexní onkologické péče, MOÚ, Brno

1 **ÚZIS**: *Novotvary 2010 ČR*. Dostupné z: www.svod.cz, vyhledáno 6. 1. 2014.
2 **Kaufmann, M. – Jonat, W. – Hilfrich, J., et al.**: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. *J Clin Oncol*, 2007, 25, s. 2664–2670.
3 **Gibson, L. – Lawrence, D. – Dawson, C., et al.**: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. *Cochrane Database Syst Rev*, 2009.
4 **Baselga, J. – Campone, M. – Piccart, M., et al.**: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Eng J Med*, 2012, 366, s. 520–529.
5 **Slamon, D. J. – Clark, G. M. – Wong, S. G., et al.**: Human breast cancer: correlation of relace and survival with amplification of the HER-2/neu oncogene. *Science*, 1987, 235, s. 177–182.
6 **Goldhirch, A. – Winer, E. P. – Coates, A. S., et al.**: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol*, 2013, 24, s. 2206–2218.
7 **Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.**: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Eng J Med*, 2001, 344, s. 783–792.
8 **Kaufman, B. – Mackey, J. R. – Clemens, M. R., et al.**: Trastuzumab plus anastrozole versus anastrozol alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: result from the randomized phase III TAnDEM study. *J Clin Oncol*, 2009, 27, s. 5529–5537.
9 **Piccart-Gebhart, M. – Procter, M. – Leyland-Jones, B., et al.**: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med*, 2005, 353, s. 1659–1672.
10 **Romond, E. H. – Perez, E. A. – Bryant, J., et al.**: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med*, 2005, 353, s. 1673–1684.
11 **Perez, E. A., et al.**: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor-2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. *J Clin Oncol*, 2011, 29, s. 3366–3373.
12 **Slamon, D. J. – Eirmann, W. – Robert, N., et al.**: Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*, 2011, 365, s. 1273–1283.
13 **Perez, E. A. – Suman, V. J. – Davidson, N. E., et al.**: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. *J Clin Oncol*, 2011, 34, s. 4491–4497.
14 **Buzdar, A. U. – Ibrahim, N. K. – Francis, D., et al.**: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol*, 2005, 23, s. 3676–3685.
15 **Gianni, L. – Eiermann, W. – Semiglazov, V., et al.**: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet*, 2010, 375, s. 377–384.
16 **Untch, M. – Rezai, M. – Loibl, S., et al.**: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. *J Clin Oncol*, 2010, 28, s. 2024–2031.
17 **Geyer, C. E. – Forster, J., et al.**: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med*, 2006, 355, s. 2733–2743.
18 **Sherril, B., et al.**: Quality of life in hormone receptor-positive HER2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. *The Oncologist*, 2010, 15, s. 944–953.
19 **Baselga, J. – Bradbury, I. – Eidtmann, H., et al.**: Lapatinib with trastuzumab for HER-2 positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. *Lancet*, 2012, 379, s. 633–640.
20 **Miller, K. – Wang, M. – Gralow, J., et al.**: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med*, 2007, 357, s. 2666–2676.
21 **Ismael, G. – Hegg, R. – Muehlbauer, S., et al.**: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. *Lancet*, 2012, 13, s. 869–678.
22 **Baselga, J. – Cortes, J. – Kim, S. B., et al.**: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2012, 366, s. 109–119.
23 **Verma, S. – Miles, D. – Gianni, L., et al.**: Trastuzumab emtansine for HER2 positive advanced breast cancer. *N Engl J Med*, 2012, 367, s. 1783–1791.

Nové možnosti v medikamentózní léčbě idiopatických střevních zánětů

prof. MUDr. Milan Lukáš, CSc.
Klinické a výzkumné centrum pro střevní záněty, ISCARE Lighthouse a 1. LF UK, Praha

1 **Bortlík, M. – Ďuricová, D. – Kohout, P., et al.**: Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. *Gastroent Hepatol*, 2012, 66, s. 12–22.
2 **Dignass, A. – Lindsay, J. O. – Sturm, A., et al.**: Second european evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. *J Crohn Colitis*, 2012, 6, s. 991–1030.
3 **Conses, J. – Bourreier, A. – Laharie, D., et al.**: Early administration of azathioprine vs conventional management of Crohn's disease: A randomized controlled trial. *Gastroenterology*, 2013, 145, s. 758–765.
4 **Panes, J. – Lopéz-San Román, A. – Bermejo, F., et al.**: Early azathioprine is not more effective than placebo for newly diagnosed Crohn's disease. *Gastroenterology*, 2013, 145, s. 775–781.
5 **Sandborn, W. – Feagan, B. G. – Marano, C. W., et al.**: A phase 2/3 randomized, placebo controlled double blid study, to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severe active ulcerative colitis. PURSUIT SC. *Gastroenterology*, 2012, 142, s. S161.
6 **Rutgeerts, P. – Feagan, B. G. – Marano, C., et al.**: A phase 3 randomized, placebo controlled, double blind study to evaluate the safety and efficacy of subcutaneous golimumab maintenance therapy in patiens with moderately to severely active ulcerative colitis: PURSUIT – MAINTENANCE. *Gut*, 2012, 44 (dopl. 2), OP 344.
7 **Reinisch, W. – Sanborn, W. J. – Holmes, D. W., et al.**: Adalimumab for induction clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. *Gut*, 2011, 60, s. 780–787.
8 **Sandborn, W. – Van Asche, G. – Reinisch, W., et al.**: Adalimumab induces and maintains clinical remission in patients with moderate—severe ulcerative colitis. *Gastroenterology*, 2012, 142, s. 257–265.
9 **Feagan, B. – Rutgeerts, P. – Sands, B., et al.**: Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl Med J*, 2013, 369, s. 699–710.
10 **Sandborn, W. J. – Feagan, B. – Rutgeerts, P., et al.**: Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl Med J*, 2013, 369, s. 711–721.
11 **Sandborn, W. J. – Gasink, C. – Gao, L. L., et al.**: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *N Engl J Med*, 2012, 18, s. 1519–1528.
12 **Sandborn, W. J. – Ghos, S. – Panes, J., et al.**: Tofacitinib, oral Janus kinase inhibitor in active ulcerative colitis. *N Engl Med J*, 2012, 367, s. 616–624.

Systémová terapie pokročilého světlobuněčného karcinomu ledviny v roce 2013

MUDr. Kateřina Kubáčková Onkologická klinika, 2. LF UK a FN Motol, Praha

1 **Sterberg, C. N. – Davis, I. D. – Mardiak, J., et al.**: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol*, 2010, 28, s. 1061–1068.
2 **Motzer, R. J. – Escudier, B. – Tomczak, P., et al.**: Axitinib versus sorafenib as second-line tretament for advanced renal cell carcinoma: overall surfoval analysis and updated results from a randomised phase 3 trial. *Lancer Oncology*, 2013, 14, s. 552–562.
3 **Motzer, R. J. – Escudier, B. – Oudard, S., et al.**: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 2008, 372, s. 449–456.
4 **Escudier, B. – Porta, C. – Bono, P., et al.**: Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310. *J Clin Oncol*, 2012, 30, CRA4502.
5 **Iacovelli, R. – Cartenì, G. – Sternberg, C. N., et al.**: Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. *Eur J Cancer*, 2013, doi: pii: S0959–8049(13)00164-0, 10.1016/j.ejca.2013.02.032.
6 **Busch, J. – Seidel, Ch. – Erber, B., et al.**: Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. *Eur Urol*, 2013, 64, s. 62–70.
7 **Cohen, H. T. – McGovern, F. J.**: Renal-cell carcinoma. *N Engl J Med*, 2005, 353, s. 2477–2490.
8 **Seidel, C. – Fenner, M. – Reuter, C., et al.**: Retrospective analyses of patient characteristics having predictive impact on survival under everolimus. *Onkologie*, 2011, 34, 111–114.
9 http://www.svod.cz/?sec=oprojektu, vyhledáno 24. 1. 2014.

Biologická léčba roztroušené sklerózy

doc. MUDr. Radomír Taláb, CSc. Neurologie, Hradec Králové
MUDr. Marika Talábová Neurologická klinika LF UK a FN, Hradec Králové

1 **Ghezzi, A., et al.**: Treatment of early-onset multiple sclerosis with intramuscular interferon β-1a: long-term results. *Neurol Sci*, 2007, 28, s. 127–132.
2 **Pohl, D. – Rostasy, K. – Partner, J. – Hanefeld, F.**: Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. *Neurology*, 2005, 64, s. 888–890.
3 **Banwell, B., et al.**: Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. *Neurology*, 2006, 66, s. 472–476.
4 **Ghezzi, A. – Amato, M. P. – Annovazzi, P. – Capobianco, M. – Gallo, P. – La Mantia, L., et al.**: Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. *Neurol Sci*, 2009, 30, s. 193–199.
5 **Ghezzi, A.**: Therapeutic strategies in childhood multiple sclerosis. *Ther Adv Neurol Disorders*, 2010, 3, s. 217–228.
6 **Taláb, R.**: Glatiramer acetát. *Farmakoterapie*, 2006, 3, s. 271–276.
7 **Farina, C. – Weber, M. S. – Meinl, E. – Wekerle, H. – Hohlfeld, R.**: Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. *Lancet Neurol*, 2005, 4, s. 567–575.
8 **Khan, O. – Shen, Y. – Caon, C. – Bao, F. – Ching, W., et al.**: Axonal metabolic recovery and potential neuroprotective affect of glatiramer acetate in relapsing-remitting multiple sclerosis. *Multiple Sclerosis*, 2005, 11, s. 646–651.
9 **Rieckmann, P. – Toyka, K. V. – Bassetti, C. – Beer, K. – Beer, S. – Buettner, U., et al.**: Escalating imunotherapy of multiple sclerosis—new aspects and practical application. *J Neurol*, 2004, 251, s. 12329–12339.
10 **Hartung, H. P. – Gonsette, R. – Konig, N. – Kwiecinski, H. – Guseo, A. – Morrissey, S. P., et al.**: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. *Lancet*, 2002, 360, s. 2018–2025.
11 **Edan, G. – Miller, D. – Clanet, D. – Confavreux, C. – Lyon-Caen, O. – Lubetzki, C., et al.**: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical kriteria. *J Neurol Neurosurg Psychiatry*, 1997, 62, s. 112–118.
12 **Tichá, V. – Šavrdová, E. – Nováková, I. – Horáková, D.**: Mitoxantron v léčbě aktivní RS. *Cesk Slov Neurol N*, 2003, 66/99, s. 31–37.
13 **Saccardi, R. – Kozák, T. – Bocelli-Tyndall, C. – Fassas, A. – Kazis, A. – Šavrdová, E., et al.**: Autologous stem cell transplantation for progressive multiple sclerosis: update of the Eurropean group for Blood and Marrow Transplantation autoimmune diseases working party database. *Mult Scler*, 2006, 12, s. 814–823.
14 **Gold, R. – Jawa, A. – Miller, D. H., et al.**: Expert opinion: guidelines for the use of natalisumab in multiple sclerosis patiens previously treated with immunomodulating therapies. *J Neuroimmunol*, 2007, 187, s. 156–158.
15 **Taláb, R.**: Natalizumab. *Farmakoterapie*, 2007, 3, s. 571–577.
16 **Mehling, M. – Lindberg, R. – Kuhle, J., et al.**: Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis. *Mult Scler*, 2008, 14, s. S234.
17 **Sallusto, F. – Geginat, J. – Lanzavecchia, A.**: Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol*, 2004, 22, s. 745–763.
18 **Cohen, J. A. – Barkhof, F. – Comi, G., et al.**: TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med*, 2010, 362, s. 402–415.
19 **Kappos, L. – Radue, E. W. – O'Connor, P., et al.**: FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med*, 2010, 362, s. 387–401.
20 **PRISMS Study Group**: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. *Lancet*, 1998, 352, s. 1498–1504.
21 **Paty, D. W. – Li, D. K. B. – IFNB MS Study Group**: Interferon-beta 1b is effective in relapsing remitting multiple sclerosis: MRI results of a multicenter, randomized, double-blind trial. *Neurology*, 1993, 43, s. 662-667.
22 **Johnson, K. P., et al., for the Copolymer I Multiple Sclerosis Study Group**: Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial. *Neurology*, 1995, 45, s. 1268–1276.
23 **Jacobs, L. D., et al.**: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. *Ann Neurol*, 1996, 39, s. 285–294.

Biologická léčba v oftalmologii

doc. MUDr. Svatopluk Synek, CSc. Klinika nemocí očních a optometrie LF MU a FN u sv. Anny, Brno

1 **Gragoudas, E. S – Adamis, A. P. – Cunningham, E. T. Jr., et al.**: VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group, Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med*, 2004, 351, s. 2805–2816.
2 **Hurwitz, H. – Fehrenbacher, L. – Novotny, W., et al.**: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*, 2004, 350, s. 2335–2342.
3 **Michels, S. – Rosenfeld, P. J. – Puliafito, C. A., et al.**: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. *Ophthalmology*, 2005, 112, s. 1035–1047.
4 **van Wijngaarden, P. – Coster, D. J. – Williams, K. A.**: Inhibitors of ocular neovascularization promises and potential problems. *JAMA*, 2005, 293, s. 1509–1513.
5 **Bakri, S. J. – Cameron, J. D. – McCannel, C. A., et al.**: Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. *Am J Ophthalmol*, 2006, 142, s. 162–164.
6 **Luthra, S. – Narayanan, R. – Marques, L. E., et al.**: Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. *Retina*, 2006, 26, s. 512–518.
7 **Shahar, J. – Avery, R. L. – Heilweil, G., et al.**: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). *Retina*, 2006, 26, s. 262–269.
8 **Manzano, R. P. – Peyman, G. A. – Khan, P. – Kivilcim, M.**: Testing intravitreal toxicity of bevacizumab (Avastin). *Retina*, 2006, 26, s. 257–261.
9 **Avery, R. L. – Pieramici, D. J. – Rabena, M. D., et al.**: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmology*, 2006, 113, s. 363–372.
10 **Maturi, R. K. – Bleau, L. A. – Wilson, D. L.**: Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. *Retina*, 2006, 26, s. 270–274.
11 **Spaide, R. F. – Laud, K. – Fine, H. F., et al.**: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina*, 2006, 26, s. 383–390.
12 **Rich, R. M. – Rosenfeld, P. J. – Puliafito, C. A., et al.**: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Retina*, 2006, 26, s. 495–511.
13 **Bashshur, Z. F. – Bazarbachi, A. – Schakal, A., et al.**: Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. *Am J Ophthalmol*, 2006, 142, s. 1–9.
14 **Yamamoto, I. – Rogers, A. H. – Reichel, E., et al.**: Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. *Br J Ophthalmol*, 2007, 91, s. 157–160.
15 **Heier, J. S. – Antoszyk, A. N. – Pavan, P. R., et al.**: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. *Ophthalmology*, 2006, 113, s. 642.
16 **Mordenti, J. – Cuthbertson, R. A. – Ferrara, N., et al.**: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. *Toxicol Pathol*, 1999, 27, s. 536–544.
17 **Mordenti, J. – Thomsen, K. – Licko, V., et al.**: Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. *Toxicol Sci*, 1999, 52, s. 101–106.
18 **Fung, A. E. – Rosenfeld, P. J. – Reichel, E.**: The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. *Br J Ophthalmol*, 2006, 90, s. 1344–1349.
19 **Klettner, A. K. – Kruse, M. L. – Meyer, T., et al.**: Different properties of VEGF antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. *Graefes Arch Clin Exp Ophthalmol*, 2009, 247, s. 1601–1608.
20 **Marcucci, R. – Bertini, L. – Giusti, B., et al.**: Thrombophilic risk factors in patients with central retinal vein occlusion. *Thromb Haemost*, 2001, 86, s. 772–776.
21 **Lahey, M. – Tunç, M. – Kearney, J., et al.**: Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. *Ophthalmology*, 2002, 109, s. 126–131.
22 **Noma, H. – Minamoto, A. – Funatsu, H., et al.**: Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. *Graefes Arch Clin Exp Ophthalmol*, 2006, 244, s. 309–315.
23 **Rehak, J. – Rehak, M.**: Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. *Curr Eye Res*, 2008, 33, s. 111–131.
24 **Boyd, S. R. – Zachary, I. – Chakravarthy, U., et al.**: Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central retinal vein occlusion. *Arch Ophthalmol*, 2002, 120, s. 1644–1645.
25 **Jager, R. D. – Aiello, L. P. – Patel, S. C., et al.**: Risks of intravitreous injection: a comprehensive review. *Retina*, 2004, 24, s. 676–698.
26 **Chan, C. K. – Abraham, P. – Meyer, C. H., et al.**: Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. *Retina*, 2010, 30, s. 203–211.
27 **Funatsu, H. – Yamashita, H. – Noma, H., et al.**: Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. *Graefes Arch Clin Exp Ophthalmol*, 2005, 243, s. 3–8.
28 **Wu, L. – Arevaldo, J. F. – Roca, J. A., et al.**: Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of Follow-Up. Retina, 2008, 28, s. 212–219.
29 **Kang, H. M. – Chung, E. J. – Kim, M., et al.**: Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion. *Graefes Arch Clin Exp Ophthalmol*, 2013, 251, s. 501–508.
30 **Hanada, N. – Iijima, H. – Sakurada, Y., et al.**: Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. *Jpn J Ophthalmol*, 2012, 56, s. 165–174.
31 **Finger, P. T. – Chin, K. J.**: Intravitreous ranibizumab (Lucentis) for radiation maculopathy. *Arch Ophthalmol*, 2010, 128, s. 249–252.

Možnosti a postavení biologických léčiv v terapii chronických virových hepatitid B a C

doc. MUDr. Petr Urbánek, CSc.

Interní klinika 1. LF UK a Ústřední vojenská nemocnice – Vojenská fakultní nemocnice, Praha

1 **Lohr, H. F. – Schmitz, D. – Arenz, M., et al.**: The viral clearance in interferon—treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. *J Hepatol*, 1999, 31, s. 407–415.
2 **Reddy, K. R.**: Controlled-release, pegylated, liposomal formulations: new mechanisms in the delivery of injctable drugs. *Ann Pharmacother*, 2000, 34, s. 915–923.
3 **Katre, N. V.**: The conjugation of proteins with polyethylene glycol and other polymers. *Adv Drug Delivery Rev*, 1993, 10, s. 91–114.
4 **Algranati, N. E. – Sy, S. – Modi, M.**: A branched methoxy 40kDa polyethylen glycol (PEG) moiety optimizes the pharmacokinetics (PK) of pegIFN alfa-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). *Hepatology*, 1999, 30, s. 190A.
5 **Chen, C. J. – Yang, H. I. – Su, J., et al.**: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA*, 2006, 295, s. 65–73.
6 **Lin, S. M. – Yu, M. L. – Lee, C. M., et al.**: Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. *J Hepatol*, 2007, 46, s. 45–52.
7 **Lin, S. M. – Sheen, I. S. – Chin, R. N., et al.**: Longterm beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. *Hepatology*, 1999, 29, s. 971–975.
8 **Niederau, C. – Heintges, T. – Lange, S., et al.**: Long term follow up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med*, 1996, 334, s. 1422–1427.
9 **Buster, E. H. – Flink, H. J. – Cakaloglu, Y., et al.**: Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. *Gastroenterology*, 2008, 135, s. 459–467.
10 **Marcellin, P. – Bonino, F. – Lau, G. K., et al.**: Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. *Gastroenterology*, 2009, 136, s. 2169–2179.
11 **Fried, M. W.**: Side effects of therapy of hepatitis C and their management. *Hepatology*, 2002, 36, s. S237–S244.
12 **Urbánek, P. – Husa, P. – Galský, J. – Šperl, J. – Hejda, V. – Kumpel, P. – Němeček, V. – Plíšek, S. – Volfová, M.**: Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C (HCV). *Gastroenterologie a Hepatologie*, 2012, 66, s. 214–229.
13 **Fried, M. W. – Shiffman, M. L. – Reddy, K. R. – Smith, C. – Marinos, G. – Goncales, F. L. – Haussinger, D. – Diago, M. – Carosi, G. – Dhumeaux, D. – Craxi, A. – Lin, A. – Hoffman, J. – Yu, J.**: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*, 2002, 347, s. 975–982.
14 **Hadziyannis, S. J. – Sette, H. – Morgan, T. R. – Balan, V. – Diago, M. – Marcellin, P. – Ramadori, G. – Bodenheimer, H. – Bernstein, D. – Rizzetto, M. – Zeuzem, S. – Pockros, P. J. – Lin, A. – Ackrill, A. – M.**: Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. *Ann Intern Med*, 2004, 140, s. 346–355.
15 **Urbánek, P. – Subhanová, I. – Janoušová, E. – Dušek, L. – Mareček Z. – Brůha, R. – Petrtýl, J. – Brodanová, M.**: Účinnost terapie pegylovaným interferonem a ribavirinem u pacientů s chronickou HCV infekcí. *Vnitř Lék*, 2009, 55, s. 474–479.
16 **Urbanek, P. – Oltman, M. – Ivanovski, L. – Rehak, V. – Messinger, D. – Tietz, A. – Husa, P.**: Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe. *European Joournal of Gastroenterology and Hepatology*, 2011, 23, s. 1004–1010.

Preventivní očkování před zahájením cílené léčby u pacientů se solidními nádory

doc. MUDr. Tomáš Büchler Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

1 **Oudard, S. – Mediáni, J. – Aylllon, J. et al.**: Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. *Expert Rev Anticancer Ther*, 2009, 9, s. 705–717.
2 **Büchler, T. – Homolka, J. – Fencl, P., et al.**: Nontuberculous mycobacterial infection after therapy with temsirolimus for metastatic renal cell carcinoma. *Tumori*, 2013, 99, s. e159–e163.
3 **Teplinsky, E. – Cheung, D. – Weisberg, I., et al.**: Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. *Breast Cancer Res Treat*, 2013, 141, s. 167–172.
4 *Afinitor: EPAR-Product Information*. European Medicines Agency. Dostupné z: www.ema.europa.eu, vyhledáno 20. 11. 2013.
5 **Saito, Y. – Nagayama, M. – Miura, Y., et al.**: A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. *Jpn J Clin Oncol*, 2013, 43, s. 559–562.
6 *Sutent: EPAR-Product Information*. European Medicines Agency. Dostupné z: www.ema.europa.eu, vyhledáno 20. 11. 2013.
7 *Avastin: EPAR-Product Information*. European Medicines Agency. Dostupné z: www.ema.europa.eu, vyhledáno 20. 11. 2013.
8 **Salvana, E. M. – Salata, R. A.**: Infectious complications associated with monoclonal antibodies and related small molecules. *Clin Microbiol Rev*, 2009, 22, s. 274–290.
9 *Xgeva: EPAR-Product Information*. European Medicines Agency. Dostupné z: www.ema.europa.eu, vyhledáno 20. 11. 2013.
10 **Cooksley, C. D. – Avritscher, E. B. – Bekele, B. N., et al.**: Epidemiology and outcomes of serious influenza-related infections in the cancer population. *Cancer*, 2005, 104, s. 618–628.
11 **Büchler, T. – Abrahámová, J.**: Vakcinace proti chřipce u dospělých pacientů se solidními nádory. *Klinická onkologie*, 2009, 22, s. 264–267.
12 **Kunisaki, K. M. – Janoff, E. N.**: Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. *Lancet Infect Dis*, 2009, 9, s. 493–504.
13 **Driver, H. G. – Weinerman, B. H.**: Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. *Can Med Assoc J*, 1978, 119, s. 733–738.
14 **Ganz, P. A. – Shanley, J. D. – Cherry, J. D.**: Responses of patients with neoplastic diseases to influenza virus vaccine. *Cancer*, 1978, 42, s. 2244–2247.
15 **Büchler, T.**: Vakcinace u dospělých pacientů se solidními nádory a profylaxe infekcí u nemocných po splenektomii. *Modrá kniha České onkologické společnosti*, 2013, 17. vydání, s. 237–238.
16 **Brakemeier, S. – Schweiger, B. – Lachmann, N., et al.**: Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix) in renal transplant recipients. *Nephrol Dial Transplant*, 2012, 27, s. 423–428.
17 **Melcher, L.**: Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. *Clin Oncol (R Coll Radiol)*, 2005, 17, s. 12–15.
18 Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*, 2012, 61, s. 816–819.
19 *Doporučení pro pneumokokovou vakcinaci v dospělosti*. Česká vakcinologická společnost ČLS JEP, 2012. Dostupné z: www.mzcr.cz/Verejne/dokumenty/doporuceni-ceske-vakcinologicke-spolecnosti-pro-pneumokokovou-vakcinaci-v-dospel_7781_1985_5.html, vyhledáno 25. 11. 2013.
20 **Sezgin Göksu, S. – Bilal, S. – Coşkun, H. Ş.**: Hepatitis B reactivation related to everolimus. *World J Hepatol*, 2013, 5, s. 43–45.

Biologická léčba idiopatické plicní fibrózy

doc. MUDr. Martina Vašáková, Ph.D.

Pneumologická klinika 1. LF UK, Thomayerova nemocnice Praha

1 **Maher, T. M.**: Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. *Clin Chest Med*, 2012, 33, s. 69–83.

2 **Richeldi, L. – Dollare, H. R. – duBois, R. M. – Jenkins, G. – Kolb, M. – Maher, T. M. – Raghu, G. – Vancheri, C. – Laurent, G. J.**: Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. *Eur Respir J*, 2013, 42, s. 230–238.

3 **Hunninghake, G. M. – Hafanu, H. – Okajima, Y., et al.**: MUC5B promoter polymorphism and interstitial lung abnormalities. *N Engl J Med*, 2013, 368, s. 2192–2200.

4 **Peljto, A. I. – Zhang, Y. – Fingerlin, T. E., et al.**: Association between the MUC5B promotor polymorphisms and survival in patients with idiopathic pulmonary fibrosis. *JAMA*, 2013, 309, s. 2232–2239.

5 **Yang, I. V. – Coldren, C. D. – Leach, S. M., et al.**: Expression of cilium associated genes defines novel molecular subytpes of idiopathic pulmonary fibrosis. *Thorax*, 2013.

6 **Vasakova, M. – Striz, I. – Slavcev, A. – Jandova, S. – Kolesar, L. – Sulc, J.**: Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. *Tissue Antigens*, 2006, 3, s. 229–232.

7 **Zhou, Y. – Huang, X. – Hecker, I., et al.**: Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonaty fibrosis. *J Clin Invest*, 2013, 123, s. 1096–1108.

8 **King, T. E. Jr. – Albera, C. – Bradford, W. Z., et al.**: Effect of interferon-g-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. *Lancet*, 2009, 374, s. 222–228.

9 **Kahloon, R. A. – Xue, J. – Bhargava, A., et al.**: Idiopathic pulmonary fibrosis patients with antibodies to heat shock protein 70 have poor prognoses. *Am J Respir Crit Care Med*, 2013, 187, s. 768–775.

10 **Laurent, G. J.**: Dynamic state of pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. *Am J Physiol*, 1987, 252, s. C1–C9.

11 **Prasse, A. – Probst, C. – Bargagli, E., et al.**: Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*, 2009, 179, s. 717–723.

12 **Toonkel, R. L. – Hare, J. M. – Matthay, M. A. – Glassberg, M. K.**: Mesenchymal stem cells and idiopathic pulmonary fibrosis: Potential for clinical testing. *Am J Respir Crit Care Med*, 2013, 188, s. 133–140.

13 *NICE technology appraisal guidance 282*. Pirfenidone for treating idiopathic pulmonary fibrosis. Vydáno: duben 2013.

14 *NICE clinical guideline 163*. Idiopathic pulmonary fibrosis: the diagnosis and management of suspected idiopathic pulmonary fibrosis. Vydáno: červen 2013.

15 **duBois, R. M. – Weycker, D. – Albera, C.**: Forced vital capacity in patients with idiopathic pulmonary fibrosis. Test properties and minimally clinically important difference. *Am J Repir Crit Care Med*, 2011, 184, s. 1382–1389.

16 **duBois, R. M. – Weycker, D. – Albera, C.**: Six-minute walk test in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*, 2011, 183, s. 1231–1237.

17 **Vancheri, C. – duBois, R. M.**: A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. *Eur Respir J*, 2013, 41, s. 262–269.

18 **Costabel, U. – Albera, C. – Bradford, W., et al.**: Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis. *Eur Respir J*, 2012, 40, s. 511.

19 **Azuma, A. – Taguchi, Y. – Ogura, T., et al.**: Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. *Respir Res*, 2011, 12, s. 143, doi: 10.1186/1465-9921-12-143.

20 **Richeldi, L. – Costabel, U. – Selman, M., et al.**: Efficacy of tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med*, 2011, 365, s. 1079–1087.

21 **Lota, H. K. – Wells, A. U.**: The evolving pharmacotherapy of pulmonary fibrosis. *Expert Opin Pharmacother*, 2013, 14, s. 79–89, doi: 10.1517/14656566.2013.758250.

22 **Antoniu, S. A.**: Nintedanib (BIBF 1120) for IPF: a tomorrow therapy? *Multidisciplinary Respiratory Medicine*, 2012, 7, s. 41, doi: 10.1186/2049-6958-7-41.

23 **Barry-Hamilton, V. – Spangler, R. – Marshall, D., et al.**: Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment. *Nature Medicine*, 2010, 16, s. 1009–1017, doi: 10.1038/nm.2208.